Scholarlink

<p>Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor that has demonstrated in combination with fulvestrant longer progression-free survival in the setting of advanced breast cancer. Although palbociclib has a relatively favorable toxicity profile, several cardiovascular events have been described including cardiomyopathy. However, adequate management of cardiotoxicity in this setting remains unclear. A 55-year-old female patient with metastatic breast cancer was admitted due to heart failure after finishing chemotherapy with palbociclib. Transthoracic echocardiography (TTE) showed a left ventricular ejection fraction (LVEF) of 30% and severe mitral regurgitation (MR). Under the suspicion of cardiomyopathy temporally associated with prior palbociclib treatment, quadruple therapy with angiotensin receptor–neprilysin inhibitor (ARNI), betablockers, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (iSLGT2) was initiated. Three months after medical therapy, the patient recovered LVEF up to 56%, and there was not MR on control TTE. This case illustrates that quadruple therapy for heart failure may be a viable option to achieve complete LVEF recovery in a case of cardiomyopathy occurring after palbociclib exposure.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiomyopathy temporally associated with prior palbociclib treatment successfully treated with quadruple therapy for heart failure: a case report

  • 期刊论文

  • 发表日期：

    2025年8月26日

查看全文
  • Iñaki Rodriguez,
  • Alberto Vera,
  • Carolina Tiraplegui,
  • Teresa Rubio,
  • Virginia Álvarez

摘要

Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor that has demonstrated in combination with fulvestrant longer progression-free survival in the setting of advanced breast cancer. Although palbociclib has a relatively favorable toxicity profile, several cardiovascular events have been described including cardiomyopathy. However, adequate management of cardiotoxicity in this setting remains unclear. A 55-year-old female patient with metastatic breast cancer was admitted due to heart failure after finishing chemotherapy with palbociclib. Transthoracic echocardiography (TTE) showed a left ventricular ejection fraction (LVEF) of 30% and severe mitral regurgitation (MR). Under the suspicion of cardiomyopathy temporally associated with prior palbociclib treatment, quadruple therapy with angiotensin receptor–neprilysin inhibitor (ARNI), betablockers, mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (iSLGT2) was initiated. Three months after medical therapy, the patient recovered LVEF up to 56%, and there was not MR on control TTE. This case illustrates that quadruple therapy for heart failure may be a viable option to achieve complete LVEF recovery in a case of cardiomyopathy occurring after palbociclib exposure.